Knight Therapeutics Inc. (TSX:GUD)

Market Cap	571.36M
Revenue (ttm)	371.30M
Net Income (ttm)	4.33M
Shares Out	99.54M
EPS (ttm)	0.04
PE Ratio	143.50
Forward PE	111.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,955
Average Volume	84,844
Open	5.75
Previous Close	5.74
Day's Range	5.66 - 5.75
52-Week Range	5.09 - 6.45
Beta	0.39
RSI	46.60
Earnings Date	Mar 21, 2025

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 745
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD